131

‘Off-the-Shelf’ CMV EphA3 CAR T Cell Therapy for Solid Tumours

QIMR

Cell therapy

Oncology

Phase 1

• Adoptive T cell therapy is a promising treatment option for solid tumours but faces numerous obstacles.

• There are 3 components to QIMR’s novel T cell therapy.

• QIMR developed a CMV-specific T-cell therapy for the treatment of solid tumours and transplant indications.

• QIMR completed 3 clinical trials using CMV immunotherapy in GBM and transplant patients with promising results.

• The CMV T cell therapy improved survival in primary GBM patients treated prior to progression.

• The CMV T cells can be used as a safe and effective delivery platform for adoptive immunotherapy.

US20200316119A1

QIMR_Overview_‘Off-the-Shelf’ CMV EphA3 CAR T Cell Therapy for Solid Tumours.pdf
QIMR_Patent_US20200316119A1.pdf
QIMR_Slide deck_‘Off-the-Shelf’ CMV EphA3 CAR T Cell Therapy for Solid Tumours.pdf